glp-1 news today oct 2 2025 trends 2025: real-world data, patient outcomes & future therapies How Supply and Demand for

Furthermore, early safety trials that included kidney outcomes as secondary endpoints hinted at potential renal benefits associated with these medication classes

PMC 4418331

Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial

FG: Formal analysis, Funding acquisition, Project administration, Resources, Validation, Visualization, Writing original draft

Despite the elevated heart rate, cardiovascular outcome trials have shown net cardiovascular benefits, suggesting that the modest chronotropic effect is outweighed by other protective mechanisms

Physiol, 274(3 Pt 2) :H 1054- 1058, 1998